RecruitingPhase 2NCT07236190
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
Studying Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Gene Bowman, ND, MPHHarvard/Massachusetts General Hospital
- Intervention
- natural product combination-1 (NPC1)(combination_product)
- Enrollment
- 40 target
- Eligibility
- 55 years · All sexes
- Timeline
- 2026 – 2027
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07236190 on ClinicalTrials.govOther trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07217548Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease PatientsOhio State University
- RECRUITINGPHASE1NCT06911008MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid CancersMayo Clinic
- ENROLLING BY INVITATIONNCT07331831Research on Attitudes, Confidence, and Practical Skills in Performing Cardiopulmonary Resuscitation and Automated External Defibrillation After Completing a Course Based on the European Resuscitation Council ModelFirst Three Minutes Foundation
- RECRUITINGNANCT07084142Developing a Digital Aid to Improve ICD DecisionsStanford University
- RECRUITINGNANCT06896825Increasing Physical Activity Through Social Support and Stress ResilienceArizona State University
- RECRUITINGNANCT07563660FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))Istanbul University - Cerrahpasa
- RECRUITINGPHASE1NCT06506461Gene Editing For Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT06771700S-ICD Implantation: US Based Pilot StudyUniversitätsklinikum Köln
See all trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome →